Browsing by Author "Bellet Ezquerra, Meritxell"
Now showing items 1-15 of 15
-
An open label, randomized phase 2 trial assessing the impact of food on the tolerability of abemaciclib in patients with advanced breast cancer
Lim, Elgene; Boyle, Frances; Okera, Meena; Loi, Sherene; Sezgin Goksu, Sema; van Hal, Gertjan; Bellet Ezquerra, Meritxell (Springer, 2022-10) -
Circulating tumor DNA reveals complex biological features with clinical relevance in metastatic breast cancer
Martínez-Sáez, Olga; Xia, Youli; Suñol-Camas, Anna; Saura Manich, Cristina; Prat, Aleix; Brasó Maristany, Fara; Sanfeliu Torres, Esther; Bellet Ezquerra, Meritxell; Oliveira, Mafalda; Matito, Judit; Vivancos, Ana (Nature Portfolio, 2023-03-01) -
High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer
Palafox Sánchez, Marta; Monserrat Vicente, Laia; Gonzalez-Perez, Abel; Antunes de Melo Oliveira, Ana Mafalda; Òdena, Andreu; Sanchez-Guixe, Monica; Capelan Rodríguez, Marta; Azaro Pedrazzoli, Analía Beatriz; Rodriguez Ferreiro, Olga; Guzman Torres, Marta; Grueso Gragera, Judit; Viaplana Donato, Cristina; Hernandez Losa, Javier; Arribas López, Joaquin Vicente; Nuciforo, Paolo Giovanni; Serra Elizalde, Violeta; Villacampa Javierre, Guillermo; Bellet Ezquerra, Meritxell; Saura Manich, Cristina; Dienstmann, Rodrigo (Nature Portfolio, 2022-09-07) -
Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast Cancer. Final Results of the Multicentre Phase II CAPRICE Study
Gil-Gil, Miguel J.; Bergamino, Milana; Morales, Serafin; Barnadas, Agustí; Manso, Luis; Bellet Ezquerra, Meritxell; Saura Manich, Cristina (Frontiers Media, 2021-07) -
Oral metronomic vinorelbine combined with endocrine therapy in hormone receptor-positive HER2-negative breast cancer: SOLTI-1501 VENTANA window of opportunity trial
Adamo, Barbara; Pascual, Tomás; Vidal, Maria; Pérez Fidalgo, José A; Gómez Pardo, Patricia; Paré, Laia; Bellet Ezquerra, Meritxell (Springer Nature, 2019-09-18) -
Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication
Ahmad Diaz, Faten; Villanueva, Rafael; Valdivia Vadell, Carolina; Palomino-Doza, Julián; Ruiz, Ada; Azaro Pedrazzoli, Analía Beatriz; Aguilar Company, Juan; Martín Pérez, Anastasio; Escriva de Romaní Muñoz, Santiago Ignacio; Alcalde Rodrigo, Maria; Ruiz Camps, Isabel; Bellet Ezquerra, Meritxell; Reyes López, Victoria (SAGE Publications, 2019-05-10) -
Palbociclib Rechallenge for Hormone Receptor-Positive/HER-Negative Advanced Breast Cancer: Findings from the Phase II BioPER Trial
Albanell, Joan; Pérez-García, José Manuel; Gil-Gil, Miguel J.; Ruiz Borrego, Manuel; Comerma Blesa, Laura; Bellet Ezquerra, Meritxell; Curigliano, Giuseppe (American Association for Cancer Research, 2023-01-04) -
Palbociclib with Fulvestrant or Letrozole in Endocrine-Sensitive Patients with HR-Positive/HER2-Negative Advanced Breast Cancer: A Detailed Safety Analysis of the Randomized PARSIFAL Trial
Pérez-García, José Manuel; Dalenc, Florence; Gil-Gil, Miguel J.; Ruiz Borrego, Manuel; Di Cosimo, Serena; Bellet Ezquerra, Meritxell (Oxford University Press, 2023-01) -
Personalized cancer therapy prioritization based on driver alteration co-occurrence patterns
Mateo, Lidia; Duran-Frigola, Miquel; Palafox Sánchez, Marta; Scaltriti, Maurizio; Razavi, Pedram; Arribas López, Joaquin Vicente; Serra Elizalde, Violeta; Gris Oliver, Albert; Bellet Ezquerra, Meritxell (BMC, 2020-09-09) -
Safety and efficacy of ribociclib plus letrozole in patients with HR+, HER2– advanced breast cancer: Results from the Spanish sub-population of the phase 3b CompLEEment-1 trial
Salvador-Bofill, Javier; Moreno, Fernando; Rodriguez Sanchez, Cesar Augusto; Galve Calvo, Elena; HERNANDO MELIA, CRISTINA; Ciruelos, Eva ; Bellet Ezquerra, Meritxell (Elsevier, 2022-12) -
SEOM clinical guidelines in advanced and recurrent breast cancer (2018)
Chacón López‑Muñiz, J. I.; de la Cruz-Merino, Luis; Gavilá Gregori, Joaquín; Martínez Dueñas, E.; Antunes de Melo Oliveira, Ana Mafalda; Seguí Palmer, M. A.; Bellet Ezquerra, Meritxell (Springer, 2019-01) -
SEOM–GEICAM–SOLTI clinical guidelines in advanced breast cancer (2022)
Garcia-Saenz, Jose Angel; Blancas, Isabel; Echavarria, Isabel; HINOJO, CARMEN; Margeli Vila, Mireia; Moreno, Fernando; Bellet Ezquerra, Meritxell (Springer, 2023-09) -
SOLTI-1805 TOT-HER3 Study Concept: A Window-of-Opportunity Trial of Patritumab Deruxtecan, a HER3 Directed Antibody Drug Conjugate, in Patients With Early Breast Cancer
Pascual, Tomás; Antunes de Melo Oliveira, Ana Mafalda; Ciruelos, Eva; Gavilá Gregori, Joaquín; Espinosa Bravo, Martin; Arumí De Dios, Míriam; Bellet Ezquerra, Meritxell; Saura Manich, Cristina (Frontiers Media, 2021-04) -
The oral selective estrogen receptor degrader GDC-0810 (ARN-810) in postmenopausal women with hormone receptor-positive HER2-negative (HR + /HER2 −) advanced/metastatic breast cancer
Bardia, Aditya; Mayer, Ingrid; Winer, Eric; Linden, Hannah; Ma, Cynthia X.; Parker, Barbara A.; Bellet Ezquerra, Meritxell (Springer, 2023-01) -
The proapoptotic gene interferon regulatory factor-1 mediates the antiproliferative outcome of paired box 2 gene and tamoxifen
Wang, Shixiong; Somisetty, Venkata S.; Bai, Baoyan; Chernukhin, Igor; Niskanen, Henri; Kaikkonen, Minna U.; Bellet Ezquerra, Meritxell (Springer Nature, 2020-10)